| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
NeoGenomics Inc (NASDAQ: NEO)
NEO Technical Analysis
2
| As on 9th Jun 2023 NEO STOCK Price closed @ 16.46 and we RECOMMEND Buy for LONG-TERM with Stoploss of 13.48 & Strong Sell for SHORT-TERM with Stoploss of 24.60 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NEOSTOCK Price
| Open | 17.41 | Change | Price | % |
| High | 17.53 | 1 Day | -0.90 | -5.18 |
| Low | 16.38 | 1 Week | -0.72 | -4.19 |
| Close | 16.46 | 1 Month | 2.16 | 15.10 |
| Volume | 488732 | 1 Year | -18.35 | -52.71 |
| 52 Week High 35.28 | 52 Week Low 6.45 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| NEO Daily Charts |
NEO Intraday Charts |
Whats New @ Bazaartrend |
NEO Free Analysis |
|
|
NEO Important Levels Intraday
| RESISTANCE | 18.68 |
| RESISTANCE | 17.97 |
| RESISTANCE | 17.53 |
| RESISTANCE | 17.09 |
| SUPPORT | 15.83 |
| SUPPORT | 15.39 |
| SUPPORT | 14.95 |
| SUPPORT | 14.24 |
NEO Forecast May 2024
| 4th UP Forecast | 35.5 |
| 3rd UP Forecast | 29.39 |
| 2nd UP Forecast | 25.62 |
| 1st UP Forecast | 21.84 |
| 1st DOWN Forecast | 11.08 |
| 2nd DOWN Forecast | 7.3 |
| 3rd DOWN Forecast | 3.53 |
| 4th DOWN Forecast | -2.58 |
NEO Weekly Forecast
| 4th UP Forecast | 22.53 |
| 3rd UP Forecast | 20.58 |
| 2nd UP Forecast | 19.38 |
| 1st UP Forecast | 18.18 |
| 1st DOWN Forecast | 14.74 |
| 2nd DOWN Forecast | 13.54 |
| 3rd DOWN Forecast | 12.34 |
| 4th DOWN Forecast | 10.39 |
NEO Forecast2024
| 4th UP Forecast | 73.11 |
| 3rd UP Forecast | 54.94 |
| 2nd UP Forecast | 43.71 |
| 1st UP Forecast | 32.48 |
| 1st DOWN Forecast | 0.44 |
| 2nd DOWN Forecast | -10.79 |
| 3rd DOWN Forecast | -22.02 |
| 4th DOWN Forecast | -40.19 |
NeoGenomics Inc ( NASDAQ USA Symbol : NEO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NEO Business Profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Address: 12701 Commonwealth Drive, Fort Myers, FL, United States, 33913
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service